# A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

> **NCT05911087** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Stemirna Therapeutics** · enrollment: 800 (estimated)

## Conditions studied

- Immunogenicity
- Safety

## Interventions

- **BIOLOGICAL:** Phase II:SWIM816;SARS-Cov-2;
- **BIOLOGICAL:** Phase II:SW-BIC-213;SARS-Cov-2;
- **BIOLOGICAL:** PhaseIII:SWIM816;SARS-Cov-2;
- **BIOLOGICAL:** PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；

## Key facts

- **NCT ID:** NCT05911087
- **Lead sponsor:** Stemirna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-20
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-02-01
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2023-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911087, "A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05911087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*